Literature DB >> 8452475

In vitro kinetics of styrene and styrene oxide metabolism in rat, mouse, and human.

A L Mendrala1, P W Langvardt, K D Nitschke, J F Quast, R J Nolan.   

Abstract

Styrene oxide (SO), a labile metabolite of styrene, is generally accepted as being responsible for any genotoxicity associated with styrene. To better define the hazard associated with styrene, the activity of the enzymes involved in the formation (monooxygenase) and destruction of SO (epoxide hydrolase and glutathione-S-transferase) were measured in the liver and lungs from naive and styrene-exposed male Sprague-Dawley rats and B6C3F1 mice (three daily 6-h inhalation exposures at up to 600 ppm styrene) and Fischer 344 rats (four daily 6-h inhalation exposures at up to 1000 ppm styrene), and in samples of human liver tissue. Additionally, the time course of styrene and SO in the blood was measured following oral administration of 500 mg styrene/kg body weight to naive Fischer rats and rats previously exposed to 1000 ppm styrene. The affinity of hepatic monooxygenase for styrene, as measured by the Michaelis constant (Km), was similar in the rat, mouse, and human. Based on the Vmax for monooxygenase activity and the relative liver and body size, the mouse had the greatest capacity and humans the lowest capacity to form SO from styrene. In contrast, human epoxide hydrolase and a greater affinity (i.e., lower Km) for SO than epoxide hydrolase from rats or mice while the apparent Vmax for epoxide hydrolase was similar in the rat, mouse, and human liver. However, the activity of epoxide hydrolase relative to monooxygenase activity was much greater in the human than in the rodent liver. Hepatic glutathione-S-transferase activity, as indicated by the Vmax, was 6- to 33-fold higher than epoxide hydrolase activity. However, the significance of the high glutathione-S-transferase activity is unknown because hydrolysis, rather than conjugation, is the primary pathway for SO detoxification in vivo. Human hepatic glutathione-S-transferase activity was extremely variable between individual human livers and much lower than in rat or mouse liver. Prior exposure to styrene had no effect on monooxygenase activity or on blood styrene levels in rats given a large oral dose of styrene. In contrast, prior exposure to styrene increased hepatic epoxide hydrolase activity 1.6-fold and resulted in lower (0.1 > P > 0.05) blood SO levels in rats given a large oral dose of styrene. Qualitatively, these data indicate that the mouse has the greatest capacity and the human the lowest capacity to form SO. In addition, human liver should be more effective than rodent liver in hydrolyzing low levels of SO.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8452475     DOI: 10.1007/bf02072030

Source DB:  PubMed          Journal:  Arch Toxicol        ISSN: 0340-5761            Impact factor:   5.153


  37 in total

1.  The metabolism of styrene oxide in the isolated perfused rat liver. Identification and quantitation of major metabolites.

Authors:  A J Ryan; J R Bend
Journal:  Drug Metab Dispos       Date:  1977 Jul-Aug       Impact factor: 3.922

2.  A rapid and simple procedure for chronic cannulation of the rat jugular vein.

Authors:  P G Harms; S R Ojeda
Journal:  J Appl Physiol       Date:  1974-03       Impact factor: 3.531

3.  Evaluation of genetic risks of alkylating agents: tissue doses in the mouse from air contaminated with ethylene oxide.

Authors:  L Ehrenberg; K D Hiesche; S Osterman-Golkar; I Wenneberg
Journal:  Mutat Res       Date:  1974-08       Impact factor: 2.433

4.  Pulmonary toxicity of inhaled styrene in acetone-, phenobarbital- and 3-methylcholanthrene-treated rats.

Authors:  E Elovaara; H Vainio; A Aitio
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

5.  Concentration-dependent metabolism and toxicity of [14C] styrene oxide in the isolated perfused rat liver.

Authors:  J Van Anda; B R Smith; J R Fouts; J R Bend
Journal:  J Pharmacol Exp Ther       Date:  1979-10       Impact factor: 4.030

6.  Microsomal styrene mono-oxygenase and styrene epoxide hydrase activities in rats.

Authors:  M Salmona; J Pachecka; L Cantoni; G Belvedere; E Mussini; S Garattini
Journal:  Xenobiotica       Date:  1976-10       Impact factor: 1.908

7.  In vitro metabolism of methylene chloride in human and animal tissues: use in physiologically based pharmacokinetic models.

Authors:  R H Reitz; A L Mendrala; F P Guengerich
Journal:  Toxicol Appl Pharmacol       Date:  1989-02       Impact factor: 4.219

8.  Hydration of arene and alkene oxides by epoxide hydrase in human liver microsomes.

Authors:  J Kapitulnik; W Levin; R Morecki; P M Dansette; D M Jerina; A H Conney
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

9.  Tissue and species differences in enzymes of epoxide metabolism.

Authors:  G M Pacifici; A R Boobis; M J Brodie; M E McManus; D S Davies
Journal:  Xenobiotica       Date:  1981-02       Impact factor: 1.908

10.  Comparison of monooxygenase activities and cytochrome P-450 isozyme concentrations in human liver microsomes.

Authors:  P H Beaune; P G Kremers; L S Kaminsky; J De Graeve; A Albert; F P Guengerich
Journal:  Drug Metab Dispos       Date:  1986 Jul-Aug       Impact factor: 3.922

View more
  7 in total

1.  CYP2E1 metabolism of styrene involves allostery.

Authors:  Jessica H Hartman; Gunnar Boysen; Grover P Miller
Journal:  Drug Metab Dispos       Date:  2012-07-17       Impact factor: 3.922

2.  Subcellular localization of rat CYP2E1 impacts metabolic efficiency toward common substrates.

Authors:  Jessica H Hartman; H Cass Martin; Andres A Caro; Amy R Pearce; Grover P Miller
Journal:  Toxicology       Date:  2015-10-14       Impact factor: 4.221

3.  Comparison of average estimated metabolic rates for styrene in previously exposed and unexposed groups with pharmacokinetic modelling.

Authors:  Y Wang; L L Kupper; A Löf; S M Rappaport
Journal:  Occup Environ Med       Date:  1996-09       Impact factor: 4.402

4.  Styrene-7,8-oxide in blood of workers exposed to styrene.

Authors:  M Korn; W Gfrörer; J G Filser; W Kessler
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

5.  A physiologic pharmacokinetic model for styrene and styrene-7,8-oxide in mouse, rat and man.

Authors:  G A Csanády; A L Mendrala; R J Nolan; J G Filser
Journal:  Arch Toxicol       Date:  1994       Impact factor: 5.153

6.  Species-specific pharmacokinetics of styrene in rat and mouse.

Authors:  J G Filser; U Schwegler; G A Csanády; H Greim; P E Kreuzer; W Kessler
Journal:  Arch Toxicol       Date:  1993       Impact factor: 5.153

7.  Acetaldehyde and hexanaldehyde from cultured white cells.

Authors:  Hye-Won Shin; Brandon J Umber; Simone Meinardi; Szu-Yun Leu; Frank Zaldivar; Donald R Blake; Dan M Cooper
Journal:  J Transl Med       Date:  2009-04-29       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.